Beuther DA, Sutherland ER Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med. 2007 Apr 1;175(7):661-6. Epub 2007 Jan 18.
Deeks SG, Lewin SR, Havlir DV The end of AIDS: HIV infection as a chronic disease. Lancet. 2013 Nov 2;382(9903):1525-33. doi: 10.1016/S0140-6736(13)61809-7. Epub 2013 Oct 23. Review.
Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 1993 Dec 15;268(35):26055-8.
Finkel T, Holbrook NJ Oxidants, oxidative stress and the biology of ageing. Nature. 2000 Nov 9;408(6809):239-47. Review.
Fried SK, Bunkin DA, Greenberg AS Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998 Mar;83(3):847-50. Review.
Grubb JR, Moorman AC, Baker RK, Masur H The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS. 2006 May 12;20(8):1095-107. Review.
Hotamisligil GS, Shargill NS, Spiegelman BM Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993 Jan 1;259(5091):87-91.
Jang JJ, Berkheimer SB, Merchant M, Krishnaswami A Asymmetric dimethylarginine and coronary artery calcium scores are increased in patients infected with human immunodeficiency virus. Atherosclerosis. 2011 Aug;217(2):514-7. doi: 10.1016/j.atherosclerosis.2011.03.035. Epub 2011 Apr 5.
Kim JA, Montagnani M, Koh KK, Quon MJ Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006 Apr 18;113(15):1888-904. Review.
Klein E, Weigel J, Buford MC, Holian A, Wells SM Asymmetric dimethylarginine potentiates lung inflammation in a mouse model of allergic asthma. Am J Physiol Lung Cell Mol Physiol. 2010 Dec;299(6):L816-25. doi: 10.1152/ajplung.00188.2010. Epub 2010 Oct 1.
Kurz K, Teerlink T, Sarcletti M, Weiss G, Zangerle R, Fuchs D Asymmetric dimethylarginine concentrations decrease in patients with HIV infection under antiretroviral therapy. Antivir Ther. 2012;17(6):1021-7. doi: 10.3851/IMP2304. Epub 2012 Aug 15.
Kurz K, Teerlink T, Sarcletti M, Weiss G, Zangerle R, Fuchs D Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers. Pharmacol Res. 2009 Dec;60(6):508-14. doi: 10.1016/j.phrs.2009.07.009. Epub 2009 Aug 3.
Lehmann S, Bakke PS, Eide GE, Gulsvik A Bronchodilator response to adrenergic beta2-agonists: relationship to symptoms in an adult community. Respir Med. 2007 Jun;101(6):1183-90. Epub 2006 Dec 22.
Nadeem A, Raj HG, Chhabra SK Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. Inflammation. 2005 Feb;29(1):23-32.
Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS. 2011 Jun 19;25(10):1281-8. doi: 10.1097/QAD.0b013e328347f3f1.
Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem. 2002 Apr 15;303(2):131-7.
Vanderweele TJ, Vansteelandt S Odds ratios for mediation analysis for a dichotomous outcome. Am J Epidemiol. 2010 Dec 15;172(12):1339-48. doi: 10.1093/aje/kwq332. Epub 2010 Oct 29.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.